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NMDA receptor antagonism with 
novel indolyl, 2-(1,1-Dimethyl-1,3-
dihydro-benzo[e]indol-2-ylidene)-
malonaldehyde, reduces seizures 
duration in a rat model of epilepsy
Hussin A. Rothan1, Elham Amini2, Fadihl L. Faraj3, Mojtaba Golpich2, Teow Chong Teoh4, 
Khadijeh Gholami5 & Rohana Yusof1
N-methyl-D-aspartate receptors (NMDAR) play a central role in epileptogensis and NMDAR antagonists 
have been shown to have antiepileptic effects in animals and humans. Despite significant progress in 
the development of antiepileptic therapies over the previous 3 decades, a need still exists for novel 
therapies. We screened an in-house library of small molecules targeting the NMDA receptor. A novel 
indolyl compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, (DDBM) 
showed the best binding with the NMDA receptor and computational docking data showed that 
DDBM antagonised the binding sites of the NMDA receptor at lower docking energies compared to 
other molecules. Using a rat electroconvulsive shock (ECS) model of epilepsy we showed that DDBM 
decreased seizure duration and improved the histological outcomes. Our data show for the first time 
that indolyls like DDBM have robust anticonvulsive activity and have the potential to be developed as 
novel anticonvulsants.
Epilepsy affects around 50 million people worldwide1. The last two decades have seen significant advances in 
new therapies for epilepsy including new antiepileptic drugs (AED)2, surgery3, cell therapy4, gene therapy5, 
and brain stimulation6. However, approximately one- third of people with epilepsy continue to have seizures 
that are intractable and experience intolerable side effects to currently available treatments7. Therefore, despite 
recent therapeutic advances, epilepsy still continues to be a major health problem and more therapies are needed 
including new anticonvulsant drugs. Although our understanding of epilepetogenesis has improved over the 
years, the complex array of pathological processes that lead to epilepsy are still largely unknown. Recently, evi-
dence supporting the role of neuroinflammation8, oxidative stress and reactive oxygen species (ROS) produc-
tion9, mitochondrial dysfunction10, damage of blood–brain barrier (BBB)11, as well as failure in the regulation of 
Gamma-aminobutyric acid (GABA) has been put forth12.
It has also been shown that N-methyl-D-aspartate receptors (NMDAR) are important subtype of the glu-
tamate receptors which play a crucial role in both pathological and physiological processes13. NMDARs are 
glutamate-gated cation channel that mediates excitatory neurotransmission in the central nervous system 
(CNS)14. Activation of the NMDARs plays an important role in the pathogenesis of a wide range of neuro-
pathological disorders including schizophrenia, stroke, depression, multiple sclerosis, Huntington’s disease15, 
Parkinson’s disease16, Alzheimer’s disease17,18, and epilepsy15,19. In epilepsy, NMDA induces seizures in a different 
pattern compared and causes different long term consequences compared to kainic acid20. Signalling activation 
in neurons results in a rapid increase of NMDA receptor, leading to excitotoxic damage through consequent 
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excessive calcium (Ca2+ ) influx. Increased Ca2+ fluxes through NMDA channels due to NMDARs phospho-
rylation appears to be a crucial mechanism underlying the epileptogenesis. Increased intracellular Ca2+ in turn 
results in pathologic outcomes such as neuronal hyperexcitability or injury, decreased seizure threshold and 
subsequent necrosis or apoptosis21–23. Recent studies demonstrated that the NMDAR is broadly expressed in 
the cerebral cortex and hippocampus, which is implicated in the pathogenesis of epilepsy14,24. However, preven-
tion of NMDAR during epileptogenesis reduced epileptic brain injury provoked by status epilepticus in rodent 
hippocampus25. Interestingly, it has been indicated that NMDAR antagonists provide an anticonvulsant activity 
to suppress seizures in several epilepsy models26. In agreement with this, several studies showed that NMDAR 
antagonists have elicited protective effects against neuronal damage induced by seizures and the subsequent 
development of epilepsy27,28.
Herein, An in silico screening was performed using in-house library of five Quinazoline derivatives and five 
Indolyl derivatives targeting the NMDA receptor. A novel indolyl, [2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol
-2-ylidene)-malonaldehyde], (DDBM) showed the best binding with the NMDA receptor and the computational 
docking data showed that DDBM antagonised the binding sites of the NMDA receptor at lower docking energies 
compared to other molecules. Using a rat electroconvulsive shock (ECS) model of epilepsy, The DDBM com-
pound showed considerable decrease in the seizure duration and improvement in the histological outcomes.
Results
Generation of DDBM. We previously reported the chemical synthesis and the structural data of Quinazoline 
molecules29 as presented in Fig. 1A. The DDBM, an Indolyl molecule, was synthesized by the Vilsmier Haack 
reaction and produced via a reaction of 1,1,2-Trimethyl-1H-benzo[e]indole, dimethylformamide and phospho-
rus trichloride (Fig. 1B).
Structural data of DDBM. The NMR data (1H-NMR and 13C-NMR spectra) of DDBM were recorded 
in deuterated CDCl3 with chemical shifts expressed in ppm using tetramethylsilane TMS as internal standard. 
1H-NMR spectra displayed signal at 13.78 ppm was assigned to (N-H) group of indole ring. A singlet signal 
appeared at 9.71 ppm was attributed to two protons of C= O carbonyl group. Signals were appeared in the region 
between 8.01 to 7.33 ppm which assigned to six protons of aromatic rings. As well as a signal at 1.95 ppm attrib-
uted to the 6 proton atoms of the two methyl groups. In addition, 13 C NMR results confirmed the 1H-NMR 
spectral results. Two signals appeared at 191.76 and 186.88 ppm which attributed to C= O carbonyl groups. Ten 
signals were observed in region between 135.40 to 111.45 ppm belong to carbon atoms of aromatic rings. In addi-
tion, three signals at 108.08, 52.32 and 20.82 ppm which attributed to aliphatic carbon atoms (Fig. 2).
Finally APT 13 C NMR result was Supported 1H-NMR and 13C-NMR results and which showed a num-
ber of carbon atoms bearing protons of CH2 groups and the quartenary carbon atoms including the solvent 
carbon appeared at the positive side (above base line), and a number of carbon atoms bearing protons of CH 
and CH3 appeared at the negative side (under base line). All NMR results were in good agreement to num-
ber of hydrogen and carbon atoms with proposed structure of 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]
indol-2-ylidene)-malonaldehyde.
Figure 1. Chemical structures of the selected compounds. (A) Chemical synthesis of Quinazoline compoud, 
HBPQ and the structural data were previously reported 18, 31. (B) The Indole compound, DDBM has been 
synthesized by Vilsmier Haack reaction method. The compound was produced in a good yield via a reaction of 
1,1,2-Trimethyl-1H-benzo[e]indole, dimethylformamide and phosphorus trichloride.
www.nature.com/scientificreports/
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Figure 2. IR Spectral Study of 2-(1,1-Dimethyl-1,3-dihydro-benzo[e] indol-2-ylidene)-malonaldehyde 
(DDBM). The results showed the main absorption bands (stretching and bending vibrations) such as NH 
absorption band at 3145 cm−1 and carbonyl groups at1650 cm−1 and 1628. In addition, C= C group at 
1608 cm−1. All these main absorption bands were in a good agreement with the proposed structure to confirm 
the formation of 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde.
www.nature.com/scientificreports/
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Molecular Docking of test compounds to NMDA receptor. Using an in-house small molecule 
library consisted of 5 Quinazoline and 5 Indolyl new compounds, we screened these molecules for affin-
ity to bind to the NMDAR. Molecular docking studies showed that Quinazoline compound, 3-(5-nitro-2-hy-
droxybenzylideneamino)-2(5-nitro-2-hydroxyphenyl)-2,3-dihydroquinazoline-4(1H)-one, (HBPQ) and an 
indolyl compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde, (DDBM) were the 
best candidates (Table 1). The DDBM compound exhibited lower docking energy compared with the stand-
ard agonist, 1-aminocyclopropane-1-carboxylic acid (ACPC) in binding with chain A as shown in Table 1, but 
shows approximately half the inhibition compared to agonist trans-1-aminocyclobutane-1,3-dicarboxylic acid 
(t-ACBD) on chain D. Thus, chain A is a better target for DDBM and at lower extent chain D. This feature for 
DDBM is important to avoid the possible side effects that have been reported due to complete inhibition of chain 
D. Thus, we selected DDBM for further investigations because it showed better binding to chain A (Glycine bind-
ing site) and less binding to chain D (Glutamate binding site) compared to HBPQ.
Further docking studies was conducted to test whether the DDBM compound can bind with other receptors 
such as Gamma-aminobutyric acid receptor (GABAR) and α -amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
receptor (AMPAR). The results showed considerable binding affinity of DDBM with GABAR (− 21.0 ± 1.3 kcal/
mol) compared to Benzamidine as a standard agonist (− 1.6 ± 1.5 kcal/mol). Whereas, the binding affinity of 
DDBM to AMPAR (− 18.4 ± 4.7 kcal/mol) was lower than the standard Perampanel (− 29 ± 8.5 kcal/mol) as pre-
sented in Table 2.
Figure 3 shows the molecular surface and van der Waals (vdw) molecular representations and 2-D diagram 
interactions of DDBM to the NMDA receptor chain A and chain D binding sites, respectively. The results showed 
that the binding of DDBM formed a more well distributed hydrogen bonds on the two separate O atoms on 
DDBM, hence the ligand-receptor complex formed by chain A is more stable. The more negative docked energy 
is due to the chain A buried surface is 562.0 ± 6.9 Å2, while chain D is 497.0 ± 95.7 Å2, higher buried surface con-
tributes to more negative desolvation energy. Larger negative desolvation energy increases the interactions and 
entropy of ligand and receptor, hence making the ligand-receptor complex more thermodynamically favourable. 
Among all the test compounds, DDBM compound served as the most potential inhibitor for chain A and showed 
partial inhibition towards chain D.
Anticonvulsant effects of DDBM compound. The anticonvulsant effects of DDBM against seizures 
elicited by electroconvulsive shock (ECS) were measured. The animals treated with DDBM performed signif-
icantly better on the behavioural symptoms of seizure (e.g. duration) compared with controlled rats. DDBM 
was administered 6 hours before the first ECS. This type of behaviour built-up progressively into motor limbic 
seizures that recurred repeatedly and rapidly developed into status epilepticus (SE). While the animals in sham 
group showed no signs of epilepsy, the ECS-administrated groups underwent varied durations of seizures. The 
ECS-administrated groups without treatment with DDBM showed durations of seizures 6.3 ± 1.8, 69.0 ± 18.1 and 
122 ± 7.5 sec for ECS1, ECS2 and ECS3 respectively. Interestingly, the duration of seizures in the animals treated 
with DDBM compound were significantly reduced (2.1 ± 0.3, 7.1 ± 1.3 and 8.7 ± 1.5 sec for ECS1, ECS2 and ECS3 
Compounds Chain A Energy (kcal/mol) Chain D Energy (kcal/mol)
DDBM − 63. 0 ± 2.8 − 31.7 ± 5.0
HBPQ − 56.6 ± 4.6 − 41.0 ± 6.3
*ACPC − 65.2 ± 3.7 —
**t-ACBD — − 53.6 ± 2.8
Table 1.  Docking energy of test compounds to chain A and chain D of NMDA receptor, with the agonist 
compounds as reference. *Reference compound binds to chain A, 1-aminocyclopropane-1-carboxylic. 
**Reference compound binds to chain D, trans-1-aminocyclobutane-1,3-dicarboxylic acid.
Receptors
Binding energy of 
DDBM Binding energy of the reference
(kcal/mol) (kcal/mol)
NMDA − 63.0 ± 2.8 − 65.2 ± 3.7
Chain A 1-aminocyclopropane-1-carboxylic acid
NMDA − 31.7 ± 5.0 − 53.6 ± 2.8
Chain D trans-1-aminocyclobutane-1,3-dicarboxylic acid
GABA − 21.0 ± 1.3 − 1.6 ± 1.5
Benzamidine
AMPA − 18.4 ± 4.7 − 29.8 ± 8.5
Perampanel
Table 2.  Docking energy of DDBM compound to NMDA receptor (chain A and chain D), GABA receptor 
and AMPA receptor.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:45540 | DOI: 10.1038/srep45540
respectively). The data of this experiment showed clearly that the treatment with DDBM compound attenuated 
the ECS-induced seizure durations particularly those induced by ECS2 & ECS3 (Fig. 4A).
Morphological and neurodegenerative changes in the hippocampus. The morphological changes 
were especially visible in the CA1 & DG hippocampal sectors compare with CA3 hippocampal sector of the ECS 
model of epilepsy. A qualitative analysis of brain histological sections in the DDBM- treated rats showed mark-
edly decreased intensity of neurodegenerative changes in the CA1, CA3 and DG hippocampal fields (Fig. 4B).
A quantitative analysis of histological sections showed a marked neuroprotective effect of DDBM. In the rats 
treated with DDBM followed by ECS, there were significant differences in the number of neurons present in the 
CA1 (p < 0.01), CA3 (p < 0.05), and DG (p < 0.01) hippocampal fields, compared to the control ECS group. 
Moreover, significant differences have been observed in this case between the hippocampal regions in the sham 
and ECS group (CA1, p < 0.01; CA3, p < 0.05; and DG, p < 0.001, One-Way ANOVA with Tukey post test). The 
number of neurons present in the CA1 hippocampal field in the sham, ECS-induced epileptic rats and treatment 
groups were 74 ± 2.1, 35.5 ± 6.3, 61 ± 5.2 neurons, respectively, whereas in the CA3 hippocampal field they were 
85 ± 2.8, 52 ± 7.5, 80.0 ± 5.7 neurons, respectively. Meanwhile, they reached 119.0 ± 4.9, 50.0 ± 5.8, 87 ± 1.4, and 
85.0 ± 2.9 neurons, respectively in the DG hippocampal field (Fig. 4B).
Discussion
Seizure control can have a profound effect on the quality of life of people with epilepsy and also reduces mor-
bidity and mortality. It has also been shown that prolonged seizures may play an important role in hippocampal 
neuronal loss, which may intern potentiate epileptogenesis30. Several animal models of epilepsy are used in epi-
lepsy research including the development of new antiepileptic drugs31. The ECS is a well-established model that 
induces generalized tonic-clonic seizure activity32 and rapidly triggers inflammatory responses in glial cells in 
brain regions affected by epileptic activity33. Furthermore, The ECS model that was used in this study also allows 
for measurement of the neuroprotective effect of a particular drug, independent of any anticonvulsant activity. 
The markers of injury can be discerned by measurement of the degree of morphological changes and the extent 
of neuronal loss34 as explained by Figs 4 and 5 in our study. In addition, seizure induces cell death and other 
events that induce neurodegeneration result from over-activation of ionotropic glutamate receptors which leads 
to increased intracellular levels of Ca+ 2 and Na+ and causes swelling and cell lysis. There is also energy failure, 
production of free radicals, activation of enzymatic complex, and cell death (both necrosis and apoptosis)35.
In this study, we screened an in-house library of small molecules to target NMDAR, a heteromeric ion channel 
that initiates seizures in human epilepsy36. The DDBM molecule, an indole derivative, that showed the best bind-
ing with NMDA receptor was characterised by IR spectra34, 1H and 13C NMR spectra35. The computational 
Figure 3. Molecular Docking of DDBM to NMDA receptor. (A) Molecular surface rendering of DDBM 
compound binding to NMDA chain A receptor binding cleft. Van der Waals (vdw) rendering of DDBM binding 
to NMDA chain A receptor binding cleft. Cyan: NMDA receptor; magenta: ligand; yellow: chain A binding site 
aa residues. The 2-D diagram of DDBM binding to NMDA chain A showing 1 vdw, 2 hydrogen bonds and 1 pi-
alkyl interactions. Docked energy, − 63.0 ± 2.8 kcal/mol. (B) Molecular surface rendering of DDBM binding to 
NMDA chain D receptor binding cleft. Van der Waals rendering of DDBM binding to NMDA chain D receptor 
binding cleft. Cyan: NMDA receptor; magenta: ligand; yellow: chain D binding site aa residues. The 2-D 
diagram of DDBM binding to NMDA chain D showing 1 vdw, 3 hydrogen bonds and 3 pi-alkyl interactions. 
Docked energy = − 31.7 ± 5.0 kcal/mol.
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docking data showed that DDBM interfered with the binding sites of NMDA receptor at lower docking energy 
compared to other compounds. This compound was able to bind with NMDA subunits (NR1 and NR2) binding 
clefts via hydrogen bonds, Van der Waals and pi-alkyl interactions leading to interfere with original ligands, 
glycine and glutamate. The results of this study showed that the binding of DDBM with NR1 (− 63 kcal/mol) and 
NR2 (− 31 kcal/mol) might eventually lead to reduced NMDAR activity by impairing the binding of glycine and 
glutamate to the NR1 and NR2 subunits, respectively37.
Many published in vivo studies in epilepsy have reported that NMDAR antagonists have potent anticonvul-
sant actions38. We assumed that the oral administration of the test compound prior to exposure of the animals to 
ECS would interfere with the NMDAR and inhibit the initiation of seizures. Treated animals that were exposed 
to three courses of ECS showed significant reduction in epileptic seizures compared to the ECS control group. 
Administration of DDBM at six hours prior to ECS induction showed the highest reduction in epileptic seizures. 
This time interval may be necessary for optimal absorption of the test compound and inhibit the induction of 
epileptic seizures. Quantitative analysis of hippocampal histological sections confirmed a considerable neuropro-
tective effect of DDBM.
Evidence that single or repeated brief seizures could cause neuronal death emerged from work in animals 
using electrical stimulation of various brain regions. It has been showed repeated stimulation of the perforant 
path, olfactory bulb or amygdala resulted in progressive decreases in neuronal density in multiple subfields of 
the hippocampus, including the hilus, CA1 and CA3, and parts of the entorhinal cortex30. These findings confirm 
that brief evoked seizures in different levels and properties can cause different level of neuronal death in various 
strains of animal models. Indeed, repeated exposures to ECS using high currents induces a kindling effect in that 
the tonic-clonic convulsion response becomes increasingly severe39. Consistent with these findings, in our study, 
cell morphology and numbers of CA1, CA3 and DG of animals treated with DDBM were significantly enhanced 
compared to untreated animals after ECS administration. The seizure-induced neuronal damage and apopto-
sis normally results from excitotoxic, glutamatergic neurotransmission, excessive Na+ and Ca2+ ions40. Thus 
Figure 4. Behavioural and histopathological changes after treatment with DDBM. (A) The animals exposed 
to ECS administration showed varied durations of seizures (6.3 ± 1.8, 69.0 ± 18.1 and 122 ± 7.5 sec for ECS1, 
ECS2 and ECS3 respectively). Treatment with DDBM showed significant reduction in the duration of seizures 
of ECS2 (7.1 ± 1.3 sec; p < 0.01) and ECS3 (8.7 ± 1.5 sec; p < 0.001) while the significant effect was not seen 
in the duration of seizures of ECS1 (2.1 ± 0.3; p > 0.05). The data of this experiment showed clearly that the 
treatment with DDBM attenuated the ECS-induced seizure durations particularly those induced by ECS2 
& ECS3 (Two-way ANOVA with Bonferroni post-tests). (B) The number of neurons present in the various 
hippocampal regions of DDBM- treated and non-treated epileptic rats. In the rats treated with the compound 
followed by ECS, there were significant differences in the number of neurons present in the CA1 (p < 0.01), CA3 
(p < 0.05), and DG (p < 0.01) hippocampal fields, compared to the ECS group. Moreover, significant differences 
have been observed in this case between the hippocampal regions in the shame and ECS group (CA1, p < 0.01; 
CA3, p < 0.05; and DG, p < 0.001, One-Way ANOVA with Tukey post test).
www.nature.com/scientificreports/
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reducing the activity of NMDA receptor by administrating DDBM may lead reduction in the excitotoxic effect 
of NMDAR and the osmolytic stress and cellular free-radical production, culminating in necrosis of neurones40.
Implement of a convenient technique that can show the actual binding affinity of DDBM compound with 
NMDAR can be considered as the main limitation of this study. We proposed this binding based on our in silico 
study and the considerable activity of the DDBM compound as anticonvulsant agent. Therefore, further investi-
gation is required to illustrate the binding affinity of DDBM compound to NMDAR and the possible interaction 
with other receptors involved in the development of epilepsy.
In conclusion, we identified a novel antiepileptic (anticonvulsant) molecule and described its chemical syn-
thesis and ability to interfere with both binding sites of NMDAR. This molecule could be a potent lead for more 
investigations towards finding novel therapeutics against epilepsy and other neurodiseases related to excitotoxic 
effects of NMDAR.
Methods
Synthesis of DDBM compound, 2-(1,1-Dimethyl-1,3-dihydro-benzo[e]indol-2-ylidene)-malon-
aldehyde. All the solvents and reagents in this research were purchased from Merck, Sigma-Aldrich and 
fisher scientific. Melting points of the synthesized compound was determined by open capillary tubes melting 
point apparatus and are uncorrected used without further purification and are uncorrected. The purity of the 
compounds was checked using pre-coated TLC plates MERCK, 60F254 using hexane: ethyl acetate (4:1) as an elu-
ent. The developed chromatography plates were visualized under UV-Vis at 254 nm., 1H and 13C-NMR spectra 
were recorded on AVN Bruker 400 FT–NMR system. Tetramethylsilane TMS was used as an internal standard, 
deuterated CDCl3 was used as a solvenst for NMR spectrophotometer. Elemental analysis CHN was performed 
on an elemental analyzer Perkin Elmer CHNS/O 2400 series II.
A solution of 1,1,2-Trimethyl-1H-benzo[e]indole (5 g, 23.9 mmol), in 15 ml anhydrous dimethylformamide 
was cooled in an ice bath. A solution of (8.78 ml, 95.6 mmol) phosphoryl chloride in anhydrous dimethylfor-
mamide 15 ml was cooled in an ice bath was added to the first solution drop wise with stirring over a period 
of 1 h at below 5 °C. The cooling bath was removed and the reaction mixture was stirred at 85 °C for 3 h. The 
resulting mixture was poured on to ice water, the pH was adjusted to 8.0 by the addition of aqueous NaOH 
(35%) whereupon the solid product was precipitated. It was filtered, washed with hot water, dried in oven to 
afford solid product. The solid product recrystallized from ethanol to give pale yellow crystals of 2-(1,1-Dimethyl-
1,3-dihydro-benzo[e]indol-2-ylidene)-malonaldehyde.
Figure 5. Morphological change in hippocampus region after treatment of epileptic rats with DDBM. 
Original magnification, x100 (A). Neurodegenerative changes in field CA1, CA3, & DG of the hippocampus in 
the DDBM- treated and non-treated rats in the ECS model of epilepsy. Original magnification x400 (B).
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Yield: (5.8 g, 91%) m.p 199–200. Anal. Calc. for C17H15NO2 (265.31): C, 76.96; H, 5.70; N, 5.28. Found: C, 76. 
65; H, 5.59; N, 5.38. IR data (cm−1): 3145 ʋ (N-H), 2980 ʋ (C-H aromatic), 2854 ʋ (C-H aliphatic) 1650 and 1628 
ʋ (C= O), 1608 ʋ (C= C), 1220 ʋ (C-N) and 738 ʋ (C-H bending). 1H NMR (400 MHz, CDCl3, ppm): δ = 13.78 (s, 
1H, NH), 9.71 (s, 2H, CHO), 8.00 (d, 1H, Ar-H), 7.87 (d, H, Ar-H), 7.80 (d, 1H, Ar-H) 7.54 (t, 1H, Ar-H), 7.41 (t, 
1H, Ar-H), 7.34 (d, 1H, Ar-H), 1.95 (s, 6H, 2x CH3) and 1.58(s, 2H, 2xCH). 13C NMR (400 MHz, CDCl3, ppm): 
δ 191.76 and 186.89 ppm (2xCHO), 180.11 ppm (N-C= C), 135.40 ppm, 132.36 ppm, 131.33 ppm, 129.23 ppm, 
128.98 ppm, 127.12 ppm, 126.51 ppm, 124.08 ppm, 121.41 ppm and 111.45 ppm (Ar-H), 108.06 ppm (C= C-C= 
O), 52.32 ppm (CH3-C-CH3) and 20.83(2x CH3).
Molecular modelling of ligands. NMDAR, GABAR and AMPAR data were obtained from Protein 
Databank (PDB: 4TLL, 4COF and 5L1F respectively). The two binding sites of NMDAR [1-aminocyclopropane-1-
carboxylic acid (ACPC) binding site on chain A and trans-1-aminocyclobutane-1,3-dicarboxylic acid (t-ACBD) 
binding site on chain D]41, the binding sites of GABAR [Benzamidine]42 and AMPAR [Perampanel]43 were 
indentified.
The ligands HBPQ and DDBM were modelled by Discovery Studio Client v4.5.0.15071 and minimized by 
CHARMm force field (Accelrys Inc., Dassault Systèmes, BIOVIA Corp., San Diego, CA, USA) were identified.
Molecular docking of NMDA receptor. The minimized ligands were targeted individually on two bind-
ing sites of NMDA receptor at F482, T516, W721, D722 for chain A and H479, R512, Y745 for chain D respec-
tively42. Haddock 2.2 molecular docking software web server was used to perform the docking simulation using 
the protein-ligand module44,45. The lowest docked energy ± standard deviation was extracted. The docked confor-
mation graphics was generated using PyMOL 1.3 ((TM) Educational Product – Copyright © 2010 Schrodinger, 
LLC) and the 2-D diagram was computed by using Discovery Studio Client v4.5.0.15071 for the van der Waals, 
hydrogen bonding and pi interactions.
Animals. Experiments were carried out on male Sprague-Dawley rats weighing 200–250 g obtained from the 
Animal Experimental Unit - University of Malaya (UM) and housed in the satellite animal holding laboratory, at 
the Departments of Pharmacology - UM. Animals were kept under a 12 hrs-12 hrs light/dark cycle and allowed 
free access to food and water. All experiments were performed in a silent room at 22–24 °C. All procedures were 
carried out with the approval from the Institutional Animal Care and Use Committee (IACUC), University of 
Malaya and all the experiments in this study were performed in accordance with relevant guidelines and regula-
tions. The animals were randomly divided into experimental groups, (a) sham group, a control group which were 
intact with no previous experimental history; (b) ECS group, which only received a chronic ECS administration; 
(c) treated groups, which were given the compound at 6 hours before administration of ECS. All efforts were 
made to minimize animal suffering and the number of animals required (n = 5 per group).
Animal model for epilepsy. The current model of epilepsy is similar to previous studies30,46 with minor 
modifications. The minimal current, duration, frequency, and interval required to produce a tonic-clonic sei-
zure in the rat is strain-dependent47,48. To determine a threshold current, duration, frequency, and interval for 
seizure in the male SD rat, we applied a preliminary study. In brief, rats received only 1 shock with the same 
current and duration used for previous studies (60 mA, 50 Hz, 1 sec). Since we have not observed the tonic-clonic 
seizure, we exposed them to the second shock with the same current and duration after three hours. Due to no 
response observed from some of the animals, we repeated it again after another three hours. The third course 
of ECS induced the tonic-clonic seizures in all animals. Therefore, the current protocol designed based on our 
dose-finding experiments. In current study, we aimed to induce tonic-clonic seizure using three repeated seizures 
(60 mA, 50 Hz, 1 sec). Interval between the ECS seizures was set only 3 hrs apart; a period during which the cell 
loss were observed in the hippocampus. This time window was selected based on the time course of the increase 
in proinflammatory cytokines which have been previously reported49.
In vivo study. In this study, we considered that the ECS administration caused severe pain to animals. 
Therefore, to reduce animal numbers, first, we conducted acute toxicity experiment and a pilot experiment to 
optimize the effective dose of the test compound and the period of drug treatment before ECS administration. 
Animals that did not display tonic-clonic seizure in response to a course of three ECS were excluded from exper-
iments as non-responders. Thus, all animals allocated for the non-treated and treated groups (all groups except 
sham) showed the tonic-clonic seizure(s). However, the seizure duration, intensity, and frequency were different 
among them.
Then, a single dose was used to determine the potential effect of the test compound. All rats in treated groups 
were given 1 ml (100 mg/Kg) of DDBM or 1 ml normal saline via oral gavage, 6 hrs before first administration 
of the first ECS. Sham treated animals received 1 ml normal saline. Seizures were induced by administration of 
the chronic ECS. The first ECS (60 mA, 50 Hz, 1 sec duration) was applied via bilateral ear clip electrodes using 
an ECS apparatus (Electroconvulsive Shock Unit, USA) to evoke a tonic seizure, followed by clonic seizures 38. 
Animals received a course of three ECS (ECS1, ECS2, & ECS3) seizures, administered at 3 hrs intervals. The ani-
mals were observed for 1 hour after induction of the last ECS (ECS3). An assessment of ECS-induced convulsions 
was performed by measuring the duration of seizures from the shock initiation to the last convulsive movements 
in each group. The sham group were applied the ear clip electrodes but without any current passing.
Tissue Preparation and Histology. Twenty four hours after the last ECS or sham session, the rats were 
anesthetized with CO2 and then decapitated using a guillotine. The brains were quickly removed and placed on 
ice. Brain samples were fixed with a fixative solution containing 4% freshly prepared paraformaldehyde (Sigma, 
USA) in pH 7.4, at least for 10 days. Brain tissue) wasparaffin embedding (Leica, Germany). 5 μ m sections were 
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cut (Leica, Germany). After being dewaxed and rehydrated, the brain tissue sections were immersed in 0.5% 
cresyl violet (Sigma, USA), rinsed with distilled water, dehydrated in ethanol solutions with increasing concen-
trations, and cleared in xylene. Next, the sections were mounted with Permount coverslip and observed under a 
light microscope (Nikon). Photographs of the histological preparations were taken in magnification x400. The 
cells were counted with the ImageJ 1.50b software using the Cell Counter function. This function allows manual 
cell counting and simultaneous marking of the already counted cells, which prevents calculation mistakes. Ten 
calculations from each of the three randomly selected fields from hippocampal sectors CA1, CA3 and dentate 
gyrus (DG) from either brain hemisphere were analyzed in all the animals.
Statistical Analysis. Values are expressed as means ± SEM of five experiments, with all measurements per-
formed in duplicate. Analyses of variance (Two- Way ANOVA and One- Way ANOVA) were performed to com-
pare results between different groups. The Bonferroni and Tukey post test were performed as a post hoc test, the 
level of significance is p < 0.05.
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